

13th PVRI Annual World Congress

on Pulmonary Vascular Disease

Hotel // The Crowne Plaza Hotel · Barcelona





Pre-Congress MEETINGS

Wednesday 30 January 2019

PVRI Board of Directors Meeting

Chair:

// Paul Hassoun PVRI PRESIDENT 2018-2019

09:00 - 17:00

PVRI Imaging Task Force Meeting

Chairs:

// David Kiely university of sheffield, uk // Andrew Peacock university of Glasgow, uk // Andrew Swift university of sheffield, uk

10:00 - 14:30





13th PVRI Annual World Congress

on Pulmonary Vascular Disease

Thursday 31 January 2019

Welcome 08:00 - 08:10

08:10 - 10:10

Plenary 1

Moderators:

// Lan Zhao imperial college, uk

// Olivier Boucherat université Laval, Canada

Adaptation to High Altitude - More than expected

Historical discovery of HPV and its physiological and pathophysiological importance

// Jason Yuan university of arizona, usa

Redox signalling in pulmonary circulation: from HPV to pulmonary hypertension

// Jeremy Ward king's college, uk

The role of vitamin D deficiency in PH

// Francisco Perez-Vizcaino university of Madrid, Spain

Mitochondria and oxygen sensing in pulmonary circulation

// Stephen Archer queen's university, canada

Genetic adaptation to high altitude

// Qadar Pasha institute of genomics & integrative biology, india

Discussion

BREAK 10:10 - 10:30





BEST ABSTRACTS (basic and clinical research)

Moderators:

- // Vinicio de Jesus Perez stanford university, usa
- // Kimio Satoh tohoku university school of medicine, Japan
- // Gérald Simonneau hôpitaux universitaires, paris-sud, france
- // Geoff Strange pulmonary hypertension society of australia & new zealand, australia
- // Anna Hemnes vanderbilt university, usa
- // Soni Savai-Pullamsetti max planck institute for heart and lung research, germany

Best abstracts presentation awards competition from our trainees.

10:30 - 12:30

10 minutes presentation and 5 minutes questions. 4 awards for the top 2 in each category.

Pulmonary Circulation Editorial Board Meeting

12:30 - 13:30

LUNCH 12:30 - 13:30

Plenary 2

Moderators:

// Paul Hassoun Johns Hopkins school of Medicine, USA
// Farid Rashidi Tabriz University of Medical Sciences, Iran

Systemic disorders in pulmonary hypertension

13:30 - 15:40

PROFESSOR GHAZWAN BUTROUS LECTURE:

Noncoding RNAs as novel treatment targets during cardiac remodelling

// Thomas Thum imtts, hanover medical school, hanover, germany

Non coding RNA and skeletal muscle disorders in PAH and consequences on exercise tolerance

// Steeve Provencher université laval, canada

Systemic manifestation in COPD-PH

// Serge Adnot institut mondor de recherche biomedicale, france

PVDOMICS

// Jane Leopold HARVARD UNIVERSITY, USA

Novel comorbidities in PAH patients

// Roham Zamanian stanford university, usa

Discussion

BREAK 15:40 - 16:00





Plenary 3

Moderators:

// Werner Seeger Justus Liebig University of Giessen, Germany

// Harm Bogaard vu university, NETHERLANDS

// Adam Torbicki ecz-otwock, medical centre for post graduate education, poland

Pro and con debate: top issues and controversies in different groups of PH

16:00 - 18:00

Pulmonary vascular alterations are an important driver of COPD (PRO)

// Norbert Weissman justus liebig university of giessen, germany

Pulmonary vascular alterations are an important driver of COPD (CON)

// Isabel Blanco Hospital Clínic, Spain

Targeting metabolic syndrome is a strategy to treat PH associated with left heart disease / HFpEF (PRO)

// Charly Lai Indiana university school of medicine, usa

Targeting metabolic syndrome is a strategy to treat PH associated with left heart disease / HFpEF (CON)

// Valentina Mercurio Frederico II UNIVERSITY, ITALY

Defective angiogenesis is a major contributor of CTEPH (PRO)

// Rozenn Quarck KU LEUVEN, BELGIUM

Defective angiogenesis is a major contributor of CTEPH (CON)

// Patricia Thistlethwaite university of california, usa

PVRI Annual General Meeting

18:00 - 19:00

Welcome & Networking Reception

19:00 - 20:30

END OF DAY 1 SCIENTIFIC SESSIONS





Friday 1 February 2019

Plenary 4

Moderators:

// Roxane Paulin université laval, canada

// Frédéric Perros hôpitaux universitaires, paris-sud, france

Epigenetics - from RV failure to pulmonary circulation: any therapeutic values?

08:10 - 10:10

PROFESSOR SHEILA GLENNIS HAWORTH LECTURE:

Cellular heterogeneity, epigenetic regulation and metabolic transitions in cardiopulmonary development and disease // Thomas Braun MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH, GERMANY

10 years of miRNAs research in PAH: any therapeutic values?

// Stephen Chan university of pittsburgh, usa

Methylation acetylation disorders in PAH

// Soni Savai-Pullamsetti max planck institute for heart and lung research, germany

Methylation and miRNAs in RV failure

// François Potus queen's university, canada

Bromodomain and PAH

// Kurt Stenmark university of colorado, denver school of medicine, usa

Discussion

BREAK 10:10 - 10:30

Plenary 5

Moderators:

// Yuichi Tamura international university of Health & Welfare, Japan

// Jason Weatherald university of calgary, canada

// Hua Luo peking university shenzhen hospital, china

// Yuriy Sirenko strazhesko institute of cardiology, ukraine

What have we learned from national PH registries?

10:30 - 12:30

What have we learned from the existing PAH registries?

// Marc Humbert hôpitaux universitaires, paris-sud, france

Registries beyond PAH: what are the existing registries and where are the knowledge gaps?

// Pilar Escribano-Subias Hospital Universitario 12 de Octubre, spain

Pitfalls in interpreting cohort and registry data

 $/\!/ Geoff Strange \ {\tt pulmonary \, Hypertension \, Society \, Of \, Australia \, \& \, New \, Zealand, \, Australia \, \\$

Establishing registries in the developing world

// Abdullah al-Dalaan king faisal specialist hospital & research centre, saudi arabia

Paediatric registries

// Maria Jesus del Cerro Marin ramony cajal university hospital, spain

Discussion





Plenary 6

Moderators:

// Stephen Archer QUEEN'S UNIVERSITY, CANADA

// + 3 judges

Rapid fire Poster presentation award session for basic science.

12:30 - 12:55

3 minutes presentation and 2 minutes questions. 2 awards for the top 2.

Meet the Editors of Pulmonary Circulation

13:00 - 14:00

Paediatric & Congenital Heart Disease Task Force Meeting

13:00 - 19:45

Chairs:

// Maria Jesus del Cerro ramony cajal university hospital, spain,

// Shahin Moledina great ormond street hospital, uk,

// Steven Abman university of colorado denver school of medicine, usa

Innovative Drug Development Initiative Working Group Meeting

14:00 - 18:00

Chairs:

// Paul Corris NEWCASTLE UNIVERSITY, UK

// Sylvia Nikkho BAYER, GERMANY

// Peter Fernandes Bellerophon Therapeutics, USA

END OF DAY TWO SCIENTIFIC SESSIONS





Saturday 2 February 2019

Plenary 7

Moderators:

// Allan Lawrie university of sheffield, uk

// Olga Tura idibaps, spain

Metabolic disorders: tomorrows heart failure and PAH therapeutic targets?

08:10 - 10:10

PROFESSOR STUART RICH LECTURE:

Potential usefulness of sound wave therapies for circulatory disorders - From angina to dementia // Hiroaki Shimokawa тоноки university, јарал

Pkm2 and heart failure: what can we learn from that?

// Gopinath Sutendra university of Alberta, Canada

AMPK and PAH

// Mark Evans university of edinburgh, uk

Selenoprotein P and mitochondrial dysfunction in PAH

// Nubuhiro Kikuchi tohoku university, Japan

The breath volatolome as a snapshot of body metabolism: Not to be neglected in PAH

// Sylvia Cohen-Kaminsky hôpitaux universitaires, paris-saclay, france

Metabolic modulators and PAH clinical trials: from DCA to Ranolazine

// Evangelos Michelakis university of Alberta, Canada

Discussion

BREAK 10:10 - 10:30

Plenary 8

Moderators:

// Marc Humbert hôpitaux universitaires, paris-sud, france

// Steeve Provencher université laval, canada

New definitions and interpretations of haemodynamic data

10:30 - 12:30

Normal PAP in healthy subjects and beyond

// Gabor Kovacs medical university of graz, austria

What is the impact of mild PAP elevation?

// Horst Olschewski medical university of graz, austria

PROs and CONs of the novel definition of PH

// Robert Naeije université libre de Bruxelles, Belgium

PAWP versus LVEDP: does it really matter?

// Ryan Tedford MEDICAL UNIVERSITY OF SOUTH CAROLINA, USA

PAH with marginal PAWP: a different disease, different phenotype or a misclassification

// Evan Brittain vanderbilt university, usa

Discussion

LUNCH 12:30 - 13:30





Plenary 9

Moderators:

// Ralph Schermuly Justus Liebig University of Giessen, Germany

// Micheala Aldred Indiana University, USA

Progenitor cells in PH: good, bad and reformable

13:30 - 15:30

Pericytes in PAH

// Vinicio de Jesus Perez stanford university, usa

The impact of BMPR2 loss on endothelial-immune interactions in PAH

// Mark Ormiston queen's university, canada

Role of circulating progenitors in pulmonary vascular repair and remodelling

// Duncan Stewart ottawa hospital research institute, canada

Resident progenitors contribute to pulmonary vascular remodelling

// Daniel Greif YALE UNIVERSITY, USA

Exosomes - outlook for future cell-free PH therapy?

// James Klinger Brown UNIVERSITY, USA

Discussion

BREAK 15:30 - 15:50

Plenary 10

Moderators:

// Ardeschir Ghofrani justus <mark>liebig u</mark>niversity of giessen, germany

// Paul Williams centre for chest disease and critical care, south africa

// Reda Girgis spectrum HEALTH, USA

Rapid fire Poster presentation award session clinical research.

15:50 - 16:15

3 minutes presentation and 2 minutes questions. 2 awards for the top 2.

Plenary 11

Moderators:

// Joe GN "Skip" Garcia university of arizona, usa

// Evangelos Michelakis university of Alberta, CANADA

From preclinical studies to drug approval in PAH: a long unpaved road

16:35 - 18:15

The industry overview of clinical development for novel targets in PAH: Considerations and expectations before initiating early-stage clinical programmes

// Michael Callahan HARVARD MEDICAL SCHOOL, USA

Repurposing drugs for an orphan disease: opportunities and pitfalls

// Edda Frauke Spiekerkoetter stanford university, usa

The landscape of clinical trials has changed in PAH: stakeholders are raising the bar

// Josep Torrent-Farnell autonomous university of barcelona, spain

Choosing the best of the best: How do we select the most promising drugs for trials in human pulmonary hypertension?

// Ardeschir Ghofrani justus liebig university of giessen, germany





Future clinical trials in PAH: what innovative strategies will be needed to succeed?

// Frances de Man vu university, netherlands

The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: Results from a national survey

// Zhenguo Zhai china-Japan Friendship Hospital, china

Moderated Poster Session

18:15 - 19:30

END OF DAY THREE SCIENTIFIC SESSIONS

${\bf PVRI\,GALA\,DINNER\,(All\,welcome,including\,partners\,\&\,guests)}$

Buy your ticket at the Reception Desk

20:00 onwards





Sunday 3 February 2019

Plenary 12

Moderators:

// Hiromi Matsubara department of cardiology, okayama medical center, Japan

// Farid Rashidi tabrız university of medical sciences, Iran

The changing landscape of treatment armatorium: is standard of care in pulmonary hypertension still debatable?

08:10 - 10:10

Initial double combination therapy is now standard of care for PAH

// Olivier Sitbon HOPITAUX UNIVERSITAIRES, PARIS-SUD, FRANCE

Rapid goal-oriented sequential therapy remains the standard for most non-high-risk PAH patients

// Richard Channick pulmonary & critical care medicine, massachusetts general hospital, usa

BPA is now the treatment of choice in CTEPH patients with non-surgically accessible disease

// David Poch university of san diego, usa

BPA should be reserved for inoperable CTEPH refractory to medical therapy

// Joanna Pepke-Zaba papworth Hospital NHS FOUNDATION TRUST, UK

Discussion

Plenary 13

Moderators:

// Anna Hemnes vanderbilt university, usa

// Stefano Ghio policlinico san matteo pavia fondazione irccs, italy

Early screening in patients at risk of PAH: Are we doing enough? Are we doing too much?

10:30 - 12:30

Systematic annual screening of all scleroderma patients with PFTs, imaging and circulating biomarkers is mandatory

// Stephen Mathai Johns HOPKINS SCHOOL OF MEDICINE, USA

The importance of risk stratification in scleroderma-associated PAH: Designing your optimal crystal ball

// Paul Hassoun Johns Hopkins school of MEDICINE, USA

Stress echo/haemodynamics identifies a subgroup of patients with pulmonary vascular disease that should be treated

// Rebecca Vanderpool university of arizona college of medicine, usa

Stress echo/haemodynamics most commonly identifies left heart dysfunction and has poor specificity for pulmonary vascular disease

// Jean-Luc Vachiery Hopital Erasme, University of Bruxelles, Belgium

Screening of pulmonary arterial hypertension in BMPR2 mutation carriers

// David Montani hopital bicêtre, hôpitaux universitaires, paris-sud, france

Discussion

END OF CONGRESS



CME Credits

This event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and is designed for a maximum of, or up to 23 European CME credits (ECMEC). Physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM.

WE LOOK FORWARD TO SEEING YOU IN **BARCELONA**



1st International Consortium for Genetic Studies in PAH

Hotel // The Crowne Plaza Hotel · Barcelona

We are pleased to announce that the first scientific meeting of the International Consortium for Genetic Studies in PAH (PAH-ICON http://www.pahicon.com) will be held in Barcelona, sponsored by the PVRI.

The meeting immediately follows the PVRI 13th Annual World Congress and will be held at the same venue.

The meeting will include presentations and abstracts from researchers in the field of PAH genetics, and will provide an opportunity for collaborative networking and participating in future international collaborations in this rapidly evolving field.

For further information go to www.pvrinstitute.org

...STAY IN

BARCELONA